drugset / Trial / NCT01012362
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase 1
Terminated
31 enrolled
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.
Timeline
- Start
- 2009-12
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | 32 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Pazopanib | Small molecule | 400 mg | Oral |
| Subject | Pazopanib | Small molecule | 600 mg | Oral |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |